- Trials with a EudraCT protocol (130)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
130 result(s) found for: Critical Period.
Displaying page 1 of 7.
EudraCT Number: 2016-003491-41 | Sponsor Protocol Number: AG-CLI-0206-LTFU | Start Date*: 2016-12-12 | |||||||||||
Sponsor Name:AnGes Inc. | |||||||||||||
Full Title: A Long Term Follow-up Study of AMG0001 in Subjects with Critical Limb Ischemia | |||||||||||||
Medical condition: Critical limb ischemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004563-31 | Sponsor Protocol Number: Au18-12 | Start Date*: 2022-07-25 |
Sponsor Name:Centre Hospitalier Universitaire de Reims | ||
Full Title: Cell therapy in Critical Limb Ischemia by implantation of allogeneic umbilical cord-derived mesenchymal stem cells | ||
Medical condition: Evaluation of the feasibility and systemic and local tolerance of an implantation, via intramuscular route, of allogenic HB-MSC1, associated with a revascularization procedure, in patients sufferin... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004684-40 | Sponsor Protocol Number: N-O_CLI_Study | Start Date*: 2018-04-19 | |||||||||||
Sponsor Name:Krakowski Szpital Specjalistyczny im. Jana Pawła II | |||||||||||||
Full Title: Regeneration of ischemic damages in cardiovascular system using Wharton’s jelly as an unlimited source of mesenchymal stem cells for regenerative medicine. Project of the National Centre for Resear... | |||||||||||||
Medical condition: Critical limb ischemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006277-24 | Sponsor Protocol Number: EFC6145 | Start Date*: 2008-04-10 | |||||||||||
Sponsor Name:sanofi-aventis recherche et développement | |||||||||||||
Full Title: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF 4 ADMINISTRATIONS OF XRP0038/NV1FGF 4mg AT 2–WEEK INTERVALS ON AMPUTATION OR ANY DEATH IN CRITICAL LI... | |||||||||||||
Medical condition: Critical Limb Ischemia with skin lesions | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) HU (Completed) GB (Completed) CZ (Completed) GR (Completed) ES (Completed) AT (Completed) FI (Completed) SE (Completed) FR (Completed) EE (Completed) IT (Completed) DK (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005786-35 | Sponsor Protocol Number: DC02RUP/IV/02 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Uriach Pharma | |||||||||||||
Full Title: Proof-of-concept, cross over, double blind, placebo-controlled study to assess if Rupatadine 20 mg can improve critical stimulation time thresholds (CSTTs) in patients with acquired cold urticaria | |||||||||||||
Medical condition: Acquired Cold Urticaria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024391-25 | Sponsor Protocol Number: 2010CLI01 | Start Date*: 2011-05-11 |
Sponsor Name:XCell-Center GmbH | ||
Full Title: A Multi-centre, double blind, randomized placebo controlled phase II study to assess the efficacy and safety of ASCT01 in Critical limb Ischemia Patients - SCILI | ||
Medical condition: Critical Limb Ischemia Rutherford clas 4-6 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005532-18 | Sponsor Protocol Number: PLX-CLI-03 | Start Date*: 2017-01-02 | |||||||||||
Sponsor Name:Pluristem Ltd. | |||||||||||||
Full Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Phase III Study to Evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatmen... | |||||||||||||
Medical condition: Critical Limb Ischemia (CLI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) AT (Completed) HU (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004596-31 | Sponsor Protocol Number: NL62772 | Start Date*: 2019-03-25 | ||||||||||||||||
Sponsor Name:UMC Utrecht | ||||||||||||||||||
Full Title: CeRebrUm and CardIac protection with Allopurinol in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass | ||||||||||||||||||
Medical condition: Brain injury in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005916-15 | Sponsor Protocol Number: MC-UK.3/AVK | Start Date*: 2008-04-25 | |||||||||||
Sponsor Name:medac Gesellschaft für klinische Spezialpräparate mbH | |||||||||||||
Full Title: Low dose Urokinase therapy by patients with diabetic foot syndrom and critical limb ischemia versus conventionel standard therapy. A randomised, open, controlled Phase III-study. | |||||||||||||
Medical condition: Patients with angiopathic or angioaneuropathic diabetic foot syndrome and critical limb ischemia without the possibility of surgical or interventional revascularisation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001538-15 | Sponsor Protocol Number: 6034 | Start Date*: 2007-06-12 |
Sponsor Name:Sangart Inc | ||
Full Title: A randomized, single-blind, controlled Phase II pilot study of Hemospan® compared with colloid (Voluven®) to evaluate vascular resistance and blood flow in the forearm, and to assess local skin blo... | ||
Medical condition: chronic critical limb ischemia (CCLI) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2009-009596-35 | Sponsor Protocol Number: | Start Date*: 2009-03-17 |
Sponsor Name:Queen Mary's, University of London | ||
Full Title: Optimisation of Peri-operative Cardiovascular Management to Improve Surgical Outcome (Optimise Trial) | ||
Medical condition: Post-operative complications in patients who undergo major surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000209-35 | Sponsor Protocol Number: 7805 | Start Date*: 2016-08-24 |
Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust | ||
Full Title: Adjuvant rituximab – a potential treatment for the young patient with Graves’ hyperthyroidism | ||
Medical condition: Graves' hyperthyroidism | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-003571-12 | Sponsor Protocol Number: GLU0409 | Start Date*: 2006-11-15 |
Sponsor Name:Barts and the London NHS Trust | ||
Full Title: Breath Methionine and Other Indices of Oxidant Stress in the Critical Care Setting. The effect of two doses of Dipeptiven given independently of parenteral nutrition. | ||
Medical condition: 60 consecutive critically ill patients will be recruited with illnesses such as severe infection, trauma and post-surgery. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-021821-10 | Sponsor Protocol Number: MSC_Apceth_001 | Start Date*: 2011-01-21 | |||||||||||
Sponsor Name:apceth GmbH & Co. KG | |||||||||||||
Full Title: Open, Randomized, Mono-centre, Two-Parallel Group Clinical Phase I/II Trial on the Evaluation of Tolerability and Efficacy of an Intravenous In-fusion of Human Bone-Marrow Derived Autologous, CD34-... | |||||||||||||
Medical condition: Critical Limb Ischemia in Patients with Advanced Peripheral Arterial Occlusive Disease Subsequent to Percutaneous Transluminal Angioplasty | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003942-35 | Sponsor Protocol Number: APHP200018 | Start Date*: 2021-04-27 | |||||||||||
Sponsor Name:Assistance Publique - Hôpitaux Paris | |||||||||||||
Full Title: HydrOcortisone and fludRocortisoNe for critical ILLness-related corticosteroid insufficiency | |||||||||||||
Medical condition: Critically ill patients with a SOFA score (SOFA; Sequential Organ Failure Assessment) ≥ 6, for at least 6 consecutive hours, suffering from CIRCI, to the notable exception of patients with septic s... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001650-98 | Sponsor Protocol Number: AC1802 | Start Date*: 2018-12-10 | ||||||||||||||||||||||||||
Sponsor Name:University of Edinburgh and NHS Lothian [...] | ||||||||||||||||||||||||||||
Full Title: Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): A randomised, parallel-group, allocation concealed, controlled, open, phase 3 pragmatic clinical and cost... | ||||||||||||||||||||||||||||
Medical condition: Any patient requiring intensive care treatment due to critical illness. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002316-12 | Sponsor Protocol Number: SR052012 | Start Date*: 2012-08-14 |
Sponsor Name:University Hospitals of the KU Leuven | ||
Full Title: The safety and feasibility of administering xenon to patients undergoing off-pump coronary artery bypass graft surgery: a pilot study XOPCAB – Xenon in Off-Pump Coronary Artery Bypass Grafting | ||
Medical condition: Xenon anesthesia in cardiac surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-000485-11 | Sponsor Protocol Number: SR022013 | Start Date*: 2013-04-24 |
Sponsor Name:University Hospitals of the KU Leuven | ||
Full Title: Xenon as an adjuvant to propofol anaesthesia in patients undergoing off-pump coronary artery bypass graft surgery: a randomized controlled trial | ||
Medical condition: Xenon anesthesia in cardiac surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005726-30 | Sponsor Protocol Number: CURES-IL1T-OT-1236 | Start Date*: 2014-04-28 |
Sponsor Name:Charité - Universitätsmedizin | ||
Full Title: A multi-center, double-blind placebo-controlled parallel group phase II study of the efficacy and safety of rilonacept in subjects with cold contact urticaria (CCU) | ||
Medical condition: cold contact urticaria (CCU) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001972-46 | Sponsor Protocol Number: SKNt-001-CP4 | Start Date*: 2019-05-14 | |||||||||||
Sponsor Name:Fresenius Kabi Deutschland GmbH | |||||||||||||
Full Title: Reaching Protein Target with SmofKabiven® extra Nitrogen Versus Olimel N9E: A Prospective, Randomised, Active-controlled, Patient-blinded, Multicentre Clinical Trial During the Early Phase of Acute... | |||||||||||||
Medical condition: Parenteral nutrition (PN) when oral or enteral nutrition (ON or EN) is impossible, insufficient, or contraindicated in the early phase of critical illness | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.